Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

Abstract : Activation of the PI3K/AKT/mTOR pathway occurs frequently in breast cancer that is resistant to endocrine therapy. Approved mTOR inhibitors effectively inhibit cell growth and proliferation but elicit AKT phosphorylation via a feedback activation pathway, potentially leading to resistance to mTOR inhibitors. We evaluated the efficacy and safety of buparlisib plus fulvestrant in patients with advanced breast cancer who were pretreated with endocrine therapy and mTOR inhibitors.
Document type :
Journal articles
Complete list of metadatas

https://hal.archives-ouvertes.fr/hal-01934677
Contributor : Mouniati Colo <>
Submitted on : Monday, November 26, 2018 - 10:36:15 AM
Last modification on : Friday, April 26, 2019 - 5:54:16 PM

Identifiers

Collections

Citation

Angelo Di Leo, Stephen Johnston, Keun Seok Lee, Eva Ciruelos, Per Lønning, et al.. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, Elsevier, 2018, 19 (1), pp.87 - 100. ⟨10.1016/S1470-2045(17)30688-5⟩. ⟨hal-01934677⟩

Share

Metrics

Record views

28